Intercalated combination of chemotherapy and icotinib followed by icotinib maintenance compared with chemotherapy followed by icotinib maintenance in EGFR mutant patients with advanced Non-Small-Cell lung cancer: a randomized, open-label, prospective study

Trial Profile

Intercalated combination of chemotherapy and icotinib followed by icotinib maintenance compared with chemotherapy followed by icotinib maintenance in EGFR mutant patients with advanced Non-Small-Cell lung cancer: a randomized, open-label, prospective study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Apr 2016

At a glance

  • Drugs Icotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Oct 2014 Status changed from not yet recruiting to recruiting, according to Chinese Clinical Trial Register record.
    • 30 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top